Ashish Sharma

*Late-breaking clinical trials announced for @ERAkidney* Looking forward to sharing main results from FIND‑CKD, plus: - Detailed analyses of effects in ~900 pts with glomerular disease - An IPD meta‑analysis across the spectrum of CKD 📍5 June, Glasgow #ERA26

RAAS blockade in the kidney Life-Cycle -Terrific work & Mentoring by @diego_moriconi @ClaraGCarro @yulnunezvill @KatherineTuttl8 #correaRotter @ERAkidney - academic.oup.com/ndt/article-ab…

😩The updated global burden of chronic kidney disease: one death every 20 seconds 🆓doi.org/10.1093/ndt/gf… @ERAkidney @OxfordJournals

2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association ahajournals.org/doi/10.1161/ST…

💫 2025 was a landmark year for glomerular diseases! Major advances for GN treatment, from IgAN and lupus nephritis to rare diseases like C3G. Can’t wait for what’s coming next! And the eGFR outcomes! Hope these new treatment options are soon available in our countries. #2025 #GlomerularDiseases #IgAN #LN #C3G #GlomLove

“Permissive Hyperkalemia” 🔆Usual approach of aggressive hyperK measures not always necessary in mild or chronic hyperK 💥Permissive hyperkalemia proposes balanced approach toward K management, looking into clinical diagnosis, drug history, symptomatology, vitals, ECG changes, & urine output 🔗 journals.lww.com/jrnm/fulltext/…

A nephrologist gives a kidney, receives hope. Very inspiring! A true shero and one of my favorite people in the world... 🙌 @AnnaGaddy healio.com/news/nephrolog…

🔥Check out the Indian guidelines for Interventional Nephrology for dialysis access and kidney biopsy ✔️ recently published in @indian journal of Nephrology indianjnephrol.org/an-avatar-foun…

❤️‍🩹Heart Failure drugs use according to CKD stage ajkd.org/action/showPdf… @AJKDonline

Fantastic to see CONFIDENCE trial results presented at #ERA25 and in @NEJM Prevention of CV events, esp. heart failure, is probably most compelling rationale for rapid initiation of combo therapy in CKD/T2D, with benefits on kidney failure accruing gradually over time

More than 50% reduction in uacr with combo and about 30% with each component that is empagliflozin and finerenone. Time to consider simultaneous initiation of combination therapy in ckd and t2d as in hfref and stage 2 hypertension.

Schematic view illustrating the events leading to crescent 🌙 formation #Nephpearls (a) Normal glomerulus (b) Glomerular disease leads to gaps or holes in the glomerular basement membrane (GBM), resulting in (c) proliferation of parietal epithelial cells and ultimately (d) fibrocellular crescent formation 👉 Source: @ACPIMPhysicians Medicine Book, Chapter on Glomerular Diseases by Raimund Pichler and @StuartShankland

Pooled analysis of DAPA-HF & DELIVER: 📍730 pts (6.7%) had severe HF
📍Dapagliflozin ⬇️ risk in both severe (HR 0.73) & nonsevere HF (HR 0.79)
📍NNT = 14
📍Safe, effective across LVEF 🔗 doi.org/10.1016/j.jchf… #JACCHF @RInciardi @mvaduganathan @MkosiborodMD @scottdsolomon

Rationale and Design of the RENAL LIFECYCLE Trial Assessing the Effect of Dapagliflozin on Cardiorenal Outcomes in Severe Chronic Kidney Disease ~1500 patients (GFR<25, dialysis, or transplant GFR<45) PEP: HHF or all-cause mortality (dialysis) and ESKD academic.oup.com/ndt/advance-ar…

If a patient developed a UTI after initiation of SGLT2 inhibitor (SGLT2i) therapy, how likely are you going to re-challenge or not ... what factors would influence your decision ⁉️ #Nephpearls #AskRenal

Basics of Glomerulonephritis (GN). GBM is key. All patterns can be explained by glomerular basement membrane (GBM) & type of injury. Let’s do one at a time CRESCENTIC GN 1. Results from breach/break of GBM (red arrow) 2. Injury is sudden & severe Eg-ANCA & anti-GBM GN

Superb job @Nephro_Sparks @anna_burgner @atlee_baker @koyaljainMD @bharvioza @Kidneylsu @AdinaVoiculescu THANK YOU @ASNKidney @proychaudhuryMD for ur vision & support🙏The 1st step to optimize dialysis access care starts with training our next generation! epc.asn-online.org/projects/tdat/

💤😴 Insomnia is common in dialysis patients-Upto 70% Why ⁉️❓ 🎯Restless les syndrome 🎯Uremia 🎯Sleep apnea common in CkD 🎯Melatonin disruption 👇VA by @NephroSeeker @NephJC

🔔Tweetorial Alert 🔔 1/ Hey #NephTwitter! Welcome to a 🆕 #tweetorial #xtorial brought to you by @KIReports.

New in @NatRevNeph With Drs Blum & @meg21212 , we explore how risk-based CKD management aligns care with risk, prioritizes absolute benefits, & improves cost-effectiveness—guiding the use of key therapies for those most likely to benefit 🔗 Read more: nature.com/articles/s4158…